24/7 Wall St. on MSN
Jim Cramer calls biotech “the hottest group in the market” as he predicts “deals are going to be flooding the market”
Quick ReadJim Cramer predicts a biotech takeover flood, with Lilly posting $19.8B Q1 revenue and Gilead closing a $7.8B ...
A federal judge has temporarily blocked Colorado’s first-in-the-nation prescription drug price cap, preventing a cap on Amgen’s Enbrel from taking effect while the company’s lawsuit against the state ...
Cemdisiran, a potential new drug for the treatment of generalized myasthenia gravis, has been accepted for priority review by ...
Zacks Investment Research on MSN
Amgen (AMGN) stock dips while market gains: Key facts
Amgen (AMGN) closed at $366.44 in the latest trading session, marking a -2.06% move from the prior day. The stock's change was less than the S&P 500's daily gain of 0.72%. Elsewhere, the Dow gained 0.
In 2024, the Colorado Prescription Drug Affordability Review Board declared Enbrel unaffordable, and last year it set an ...
LIV Golf player delighted to be back getting best possible links prepration for The Open ...
According to BCC Research, the global chronic kidney disease market is projected to grow steadily through 2030, driven by the ...
Boehringer Ingelheim has landed an exclusive license to Prime Vector Technologies’ (PVT) viral vector platform for developing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results